Unlike pan‐PI3K inhibitors, taselisib is believed to have fewer side effects and greater efficacy in treating PIK3CA‐mutant cancers, owing to its selective action on these specific PI3K isoforms [348]. This evidence concerns the gene PIK3CG and cancer.